Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.48 USD
Change Today -0.07 / -1.54%
Volume 24.3K
ADMP On Other Exchanges
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

adamis pharmaceuticals corp (ADMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $7.26
52 Week Low
08/15/14 - $2.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

adamis pharmaceuticals corp (ADMP) Related Businessweek News

No Related Businessweek News Found

adamis pharmaceuticals corp (ADMP) Details

Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology, and immunology. The company’s specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. Its vaccine product candidates and cancer drug product candidates comprise TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs; and APC-100, APC-200, and APC-300, for the treatment of prostate cancer. The company is headquartered in San Diego, California.

adamis pharmaceuticals corp (ADMP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $553.8K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $222.8K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $262.3K
Compensation as of Fiscal Year 2014.

adamis pharmaceuticals corp (ADMP) Key Developments

Adamis Pharmaceuticals Corporation Announces Positive Clinical Study Results for its Albuterol (Salbutamol) HFA Product

Adamis Pharmaceuticals Corporation announced the results of a clinical efficacy trial that was conducted outside of the United States for its albuterol HFA product, APC-2000. The study was performed in 124 stable, mild to moderate asthmatic subjects and was designed to reflect the FDA's Albuterol Sulfate June 2013 Draft Guidance. The primary objective of the study was to evaluate the therapeutic equivalence of Adamis' APC-2000 HFA with GlaxoSmithKline's (GSK) Ventolin Evohaler HFA. To achieve this, the primary endpoint chosen was the equivalence of change from baseline in Forced Expiratory Volume (FEV1 AUC 0-6 hours) between the two HFA aerosols assessed at two different doses (100 and 200 mcg). The study was a randomized double blind, double dummy, four periods crossover, therapeutic equivalence study comparing Adamis' APC-2000 HFA with GSK's Salbutamol Sulphate HFA (Ventolin Evohaler). Two doses of each product were tested, 100 and 200 mcg doses. Each subject received 4 inhalers at each of the 4 periods. These contained two Ventolin (one or both was active or placebo) and two APC-2000 inhalers (one or both was active or placebo). Periods were randomized to reflect the order in which inhalers were taken in each period. There were two washout days between the periods. The study met the clinical FEV1 primary endpoint and results confirmed the therapeutic equivalence between the test (APC-2000) and the reference product (GSK's Ventolin Evohaler). Both products were found to be safe and well-tolerated. The study also confirmed a significant difference in clinical efficacy between the two doses.

Adamis Pharmaceuticals Corporation Announces Executive Appointments

Adamis Pharmaceuticals Corporation announced that Gus Fernandez, Pharm.D., MBA, has joined Adamis as Vice President of Commercial Operations. In this role, he will work closely with other senior management members to direct all aspects of commercial sales. Most recently, he served as National Business Director for inVentiv Health Commercial Services where he formed, recruited and retained sales teams. Prior to inVentiv, he was VP of Commercial Development and Operations for Avanir Pharmaceuticals where he was responsible for new product planning and commercial operations. Before Avanir, he held several managing roles over a six year period for Dura Pharmaceuticals including Director of Sales Operations. At Dura, he directed a staff of thirteen which supported over 400 sales professionals. He also spent six years as a sales representative for Eli Lilly & Company. Louis J. Fayant, MBA, has joined Adamis as Director of Account Management. For several years, he was Director of Managed Care for Dey L.P. which became a subsidiary of Mylan. There, he oversaw all operations of Dey's US Managed Care Department which impacted over 50% of the company's branded sales, including the EpiPen®. Prior to Dey L.P., he served as Director of Pharmacy Benefit Management for Dura Pharmaceuticals for four years. David J. DeLay has also joined Adamis as Senior National Accounts Manager Alternative Markets. Most recently, he was Director of National Accounts for Halozyme Therapeutics.

Adamis Pharmaceuticals Receives Complete Response Letter from FDA for its Epinephrine Pre-Filled Syringe NDA

Adamis Pharmaceuticals Corporation announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product, for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction. On May 28, 2014, Adamis submitted an NDA to the FDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of the Epinephrine PFS product. A CRL is issued by the FDA'sCenter for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form. The questions raised by the FDA pertain only to Chemistry, Manufacturing and Controls (CMC) relating to the volume of dose delivered by the syringe, including the ability to deliver volume within the levels contained in the labeling claim and as required by the FDA. No other safety or efficacy issues were raised, and the New Drug Application will remain open until the CMC issues are resolved.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMP:US $4.48 USD -0.07

ADMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Delcath Systems Inc $0.93 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMIS PHARMACEUTICALS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at